Keywords: Boehringer Ingelheim, Pradaxa, Bleeding rates, USA, FDA, RE-LYtrial

FDA confirms views that Boehringer's Pradaxa bleeding rates no higher than for warfarin

Article | 19 March 2013

Print This

A new perspective from the US Food and Drug Administration states the agency has not changed its recommendations regarding German ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in